Skip to main content
    A

    Amgen Inc (AMGN)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NASDAQ

    $462.32
    -3.35 (-0.72%)

    Market Cap: $251.89B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Amgen Inc (AMGN) Earnings: Report Dates and Results

    Updated Nov 3, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Amgen (AMGN) is expected to report earnings on Feb 1, 2027. In the quarter ended Sep 30, 2026, Amgen reported EPS of $6.45, above the $5.74 estimate. It beat the EPS estimate in each of the last 9 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    90%(36/40)
    Avg Surprise
    +6.94%
    Streak
    9 Q

    Upcoming Estimates

    Reports Feb 1, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$5.72
    Range$5.03 - $6.38
    30 analysts
    Revenue Consensus
    $10.69B
    Range$10.00B - $11.31B
    28 analysts
    Reports Apr 28, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$5.70
    Range$5.13 - $6.09
    10 analysts
    EPS Revisions
    3
    2
    30d
    EPS Estimate DriftChange to current
    90d ago$5.59+1.9%
    60d ago$5.60+1.9%
    30d ago$5.61+1.7%
    7d ago$5.69+0.3%
    Current$5.70
    Revenue Consensus
    $9.48B
    Range$8.78B - $10.07B
    7 analysts

    Next Report

    AMGN has an expected report date of Feb 1, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 8.1% above the $5.29 reported for the quarter ended Dec 31, 2025.

    AMGN Earnings Call

    The latest AMGN earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, AMGN beat 36, missed 3 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $10.37B, up 8.5% from $9.56B a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$6.45$5.74$5.47 - $6.09+12.37%Beat+14.4%292 up, 3 downNov 3, 2026$10.37B
    Jun 30, 2026$6.29$5.60$4.99 - $6.28+12.32%Beat+4.5%285 up, 5 downAug 4, 2026$10.05B
    Mar 31, 2026$5.15$4.77$4.17 - $5.24+7.97%Beat+5.1%2910 up, 7 downApr 30, 2026$8.62B
    Dec 31, 2025$5.29$4.73$4.05 - $5.74+11.84%Beat-0.4%238 up, 3 downFeb 3, 2026$9.87B
    Sep 30, 2025$5.64$5.01$4.38 - $5.42+12.57%Beat+1.1%268 up, 5 downNov 4, 2025$9.56B
    Jun 30, 2025$6.02$5.28$4.81 - $5.84+14.02%Beat+21.1%2713 up, 2 downAug 5, 2025$9.18B
    Mar 31, 2025$4.90$4.26$3.89 - $5.11+15.02%Beat+23.7%246 up, 5 downMay 1, 2025$8.15B
    Dec 31, 2024$5.31$5.08$4.71 - $5.79+4.53%Beat+12.7%227 up, 4 downFeb 4, 2025$9.09B
    Sep 30, 2024$5.58$5.11$4.91 - $5.42+9.20%Beat+12.5%215 up, 1 downOct 30, 2024$8.50B
    Jun 30, 2024$4.97$5.00$4.80 - $5.43-0.60%Miss-0.6%2111 up, 0 downAug 6, 2024$8.39B
    Mar 31, 2024$3.96$3.89$3.32 - $4.87+1.80%Beat-0.5%215 up, 0 downMay 2, 2024$7.45B
    Dec 31, 2023$4.71$4.59$4.33 - $5.09+2.61%Beat+15.2%204 up, 0 downFeb 6, 2024$8.20B
    Sep 30, 2023$4.96$4.68N/A+5.98%Beat+5.5%195 up, 3 downOct 31, 2023$6.90B
    Jun 30, 2023$5.00$4.49$3.92 - $4.84+11.36%Beat+7.5%207 up, 3 downAug 3, 2023$6.99B
    Mar 31, 2023$3.98$3.85$3.30 - $4.49+3.38%Beat-6.4%201 up, 2 downApr 27, 2023$6.11B
    Dec 31, 2022$4.09$4.09$3.94 - $4.250.00%In line-6.2%203 up, 1 downJan 31, 2023$6.84B
    Sep 30, 2022$4.70$4.45$4.23 - $4.75+5.62%Beat+0.6%218 up, 4 downNov 3, 2022$6.65B
    Jun 30, 2022$4.65$4.33$3.95 - $4.87+7.39%Beat+6.2%219 up, 1 downAug 4, 2022$6.59B
    Mar 31, 2022$4.25$4.12$3.70 - $4.55+3.16%Beat+14.9%184 up, 3 downApr 27, 2022$6.24B
    Dec 31, 2021$4.36$4.04$3.66 - $5.08+7.92%Beat+14.4%214 up, 1 downFeb 7, 2022$6.85B
    Sep 30, 2021$4.67$4.22$3.95 - $4.92+10.66%Beat+6.9%20N/ANov 2, 2021$6.71B
    Jun 30, 2021$4.38$4.01$3.83 - $4.49+9.23%Beat+3.1%21N/AAug 3, 2021$6.53B
    Mar 31, 2021$3.70$4.04$3.68 - $4.41-8.42%Miss-11.3%21N/AApr 27, 2021$5.90B
    Dec 31, 2020$3.81$3.35$3.09 - $4.07+13.73%Beat+4.7%25N/AFeb 2, 2021$6.63B
    Sep 30, 2020$4.37$3.75$3.47 - $4.16+16.53%Beat+19.4%24N/AOct 28, 2020$6.42B
    Jun 30, 2020$4.25$3.77$3.10 - $4.31+12.73%Beat+7.1%23N/AJul 28, 2020$6.21B
    Mar 31, 2020$4.17$3.75$3.19 - $4.09+11.20%Beat+17.1%21N/AApr 30, 2020$6.16B
    Dec 31, 2019$3.64$3.42$3.07 - $3.83+6.43%Beat+6.4%18N/AJan 30, 2020$6.20B
    Sep 30, 2019$3.66$3.53$3.17 - $3.72+3.68%Beat-0.8%21N/AOct 29, 2019$5.74B
    Jun 30, 2019$3.97$3.58$3.33 - $3.78+10.89%Beat+3.7%19N/AJul 30, 2019$5.87B
    Mar 31, 2019$3.56$3.48$3.04 - $3.76+2.30%Beat+2.6%19N/AApr 30, 2019$5.56B
    Dec 31, 2018$3.42$3.27$3.16 - $3.42+4.59%Beat+18.3%18N/AJan 29, 2019$6.23B
    Sep 30, 2018$3.69$3.45$3.12 - $3.71+6.96%Beat+12.8%18N/AOct 30, 2018$5.90B
    Jun 30, 2018$3.83$3.56$3.10 - $3.67+7.58%Beat+17.1%18N/AJul 26, 2018$6.06B
    Mar 31, 2018$3.47$3.25$2.97 - $3.50+6.77%Beat+10.2%18N/AApr 24, 2018$5.55B
    Dec 31, 2017$2.89$3.03$2.90 - $3.23-4.62%Miss0.0%19N/AFeb 1, 2018$5.80B
    Sep 30, 2017$3.27$3.10$2.87 - $3.24+5.48%Beat+8.3%20N/AOct 25, 2017$5.77B
    Jun 30, 2017$3.27$3.11$2.99 - $3.22+5.14%Beat+15.1%20N/AJul 25, 2017$5.81B
    Mar 31, 2017$3.15$3.01N/A+4.65%Beat+8.6%N/AN/AApr 26, 2017$5.46B
    Dec 31, 2016$2.89$2.79N/A+3.58%Beat+10.7%N/AN/AFeb 2, 2017$5.96B
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $21.85, up 10.2% from the year before. It was $11.65 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$21.85+10.2%
    Dec 31, 2024$19.82+6.3%
    Dec 31, 2023$18.65+5.4%
    Dec 31, 2022$17.69+3.4%
    Dec 31, 2021$17.11+3.1%
    Dec 31, 2020$16.60+11.9%
    Dec 31, 2019$14.83+2.9%
    Dec 31, 2018$14.41+14.5%
    Dec 31, 2017$12.58+8.0%
    Dec 31, 2016$11.65N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,400 words across 18 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20268,35818
    2026Q2Jun 30, 20268,28518
    2026Q1Mar 31, 20268,94617
    2025Q4Dec 31, 20258,83817
    2025Q3Sep 30, 20259,08316
    2025Q2Jun 30, 20257,92222
    2025Q1Mar 31, 20256,31617
    2024Q4Dec 31, 20248,57821

    2026Q3 Earnings Call

    Opening remarks

    Casey Capparelli Vice President of Investor Relations Thank you, Julianne. Good afternoon, everyone, and welcome to our third quarter of 2026 earnings call. Bob Bradway will lead the call today and be followed by a broader review of our performance by Murdo Gordon, Jay Bradner, and Thomas Dittrich. Through the course of our discussion today, we will use non-GAAP financial measures to describe our performance and have provided appropriate reconciliations within the materials that accompany this call. We will also make some forward-looking statements, which are qualified by our safe harbor statement. Please note that actual results can vary materially. Over to you, Bob.

    Robert Bradway CEO Good afternoon, and thank you for joining our call. Our results through the first 3 quarters of the year reflect the strength of our business across a broad range of products and pipeline molecules. This is exactly the kind of performance our strategy was designed to achieve. Strong commercial and operations execution and continued innovation from our research and development organization reinforce our confidence in Amgen's ability to deliver durable long-term growth. For the latest quarter, total revenues grew a strong 8% year-over-year to $10.4 billion. Our 6 key growth drivers grew 27% year-over-year and represented over 70% of our third quarter product sales. Across the portfolio, 17 products delivered double-digit sales growth and 17 products are now annualizing at more than $1 billion based on third quarter sales. We see significant opportunity to build on this momentum. Many of our medicines address large, underpenetrated disease areas where the majority of patients remain untreated. Repatha, EVENITY, and TEZSPIRE are clear examples of that. Our strong financial performance gives us the flexibility to invest in innovation and the capabilities needed to support future growth while delivering attractive returns to shareholders. In the third quarter, we generated $3.7 billion in free cash flow, increased our investment in research and development by 11% year-over-year, and invested another $600 million in the business through capital expenditures. This was another productive quarter for our R&D organization. We reported positive Phase III results from 3 important programs: IMDELLTRA, in small cell lung cancer, where we are working to establish it as the cornerstone therapy; TEZSPIRE, in eosinophilic esophagitis, an area with significant unmet need; and dazodalibep, in Sjogren's disease, where no approved disease-modifying therapies currently exist. I would note that each of these represents an established or potential first-in-class medicine with the opportunity to make a meaningful difference for patients while providing additional sources of long-term growth for Amgen. Likewise, our progress reflects the strength of our science and our commitment to pursuing novel approaches for serious diseases. That same focus guides our investment in programs such as MariTide, which is advancing through Phase III development.

    Frequently Asked Questions About AMGN

    When is Amgen's next earnings date?

    Amgen's next earnings report is expected for Feb 1, 2027.

    Did AMGN beat earnings estimates last quarter?

    Yes. Amgen reported EPS of $6.45 for the quarter ended Sep 30, 2026, above the $5.74 estimate, a 12.37% surprise.

    What EPS do analysts expect from AMGN next quarter?

    The consensus EPS estimate for Amgen for the quarter ending Dec 31, 2026 is $5.72 from 30 analysts, with estimates from $5.03 to $6.38.

    How often does AMGN beat earnings estimates?

    Amgen beat the EPS estimate in each of the last 9 quarters, with an average surprise of +11.09%.